What is the definition of Autoimmune Hemolytic Anemia?

Autoimmune hemolytic anemia (AIHA) occurs when your immune system makes antibodies that attack your red blood cells. This causes a drop in the number of red blood cells, leading to hemolytic anemia. Symptoms may include unusual weakness and fatigue with tachycardia and breathing difficulties, jaundice, dark urine and/or splenomegaly. AIHA can be primary (idiopathic) or result from an underlying disease or medication. The condition may develop gradually or occur suddenly. There are two main types of autoimmune hemolytic anemia: warm antibody hemolytic anemia and cold antibody hemolytic anemia. Treatment may include corticosteroids such as prednisone, splenectomy, immunosuppressive drugs and/or blood transfusions.

What are the alternative names for Autoimmune Hemolytic Anemia?

  • Anemia hemolytic autoimmune
  • Acquired autoimmune hemolytic anemia
  • Idiopathic autoimmune hemolytic anemia
  • Familial auto-immune hemolytic anemia (subtype)
  • Immuno-hemolytic anemia

What are the causes for Autoimmune Hemolytic Anemia?

In about half of cases, the cause of autoimmune hemolytic anemia cannot be determined (idiopathic or primary). This condition can also be caused by or occur with another disorder (secondary) or rarely, occur following the use of certain drugs (such as penicillin) or after a person has a blood and marrow stem cell transplant. Secondary causes of autoimmune hemolytic anemia include: 

  • Autoimmune diseases, such as lupus
  • Chronic lymphocytic leukemia
  • Non-Hodgkin's lymphoma and other blood cancers
  • Epstein-Barr virus
  • Cytomegalovirus
  • Mycoplasma pneumonia
  • Hepatitis
  • HIV

What is the outlook (prognosis) for Autoimmune Hemolytic Anemia?

The outlook depends on the underlying cause of the disease and whether symptoms are managed appropriately and in a timely manner. Death as a result of autoimmune hemolytic anemia is rare.

Is Autoimmune Hemolytic Anemia an inherited disorder?

In many cases, the cause of autoimmune hemolytic anemia remains unknown. Some researchers believe that there are multiple factors involved, including genetic and environmental influences (multifactorial). In a very small number of cases, autoimmune hemolytic anemia appears to run in families. In these cases, it appears to follow an autosomal recessive pattern of inheritance.

If you have concerns about the specific risks in your family, we encourage you to consult with a genetics professional.
  • Condition: Cold Agglutinin Disease
  • Journal: The New England journal of medicine
  • Treatment Used: Sutimlimab
  • Number of Patients: 24
  • Published —
The aim of this study was to examine the effect of sutimlimab in patients with cold agglutinin disease.
  • Condition: Cold Agglutinin Disease
  • Journal: Frontiers in immunology
  • Treatment Used: Daratumumab
  • Number of Patients: NULL
  • Published —
The study researched the effects of daratumumab in patients with cold agglutinin disease.
Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Other
  • Participants: 20
  • Start Date: April 20, 2022
Umbilical Cord Blood Treatment for Refractory Immune Cytopenia: a Single-arm Prospective Study
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 22
  • Start Date: June 30, 2021
A Phase 2 Trial of Acalabrutinib for the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia